443 related articles for article (PubMed ID: 24751830)
21. The use of human albumin for the treatment of ascites in patients with liver cirrhosis: item of safety, facts, controversies and perspectives.
Facciorusso A; Nacchiero MC; Rosania R; Laonigro G; Longo N; Panella C; Ierardi E
Curr Drug Saf; 2011 Sep; 6(4):267-74. PubMed ID: 22129322
[TBL] [Abstract][Full Text] [Related]
22. Pathogenesis and treatment of hepatorenal syndrome.
Arroyo V; Fernandez J; Ginès P
Semin Liver Dis; 2008 Feb; 28(1):81-95. PubMed ID: 18293279
[TBL] [Abstract][Full Text] [Related]
23. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications.
Garcia-Martinez R; Caraceni P; Bernardi M; Gines P; Arroyo V; Jalan R
Hepatology; 2013 Nov; 58(5):1836-46. PubMed ID: 23423799
[TBL] [Abstract][Full Text] [Related]
24. Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis.
Fernández J; Navasa M; Garcia-Pagan JC; G-Abraldes J; Jiménez W; Bosch J; Arroyo V
J Hepatol; 2004 Sep; 41(3):384-90. PubMed ID: 15336440
[TBL] [Abstract][Full Text] [Related]
25. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis.
Ginès P; Uriz J; Calahorra B; Garcia-Tsao G; Kamath PS; Del Arbol LR; Planas R; Bosch J; Arroyo V; Rodés J
Gastroenterology; 2002 Dec; 123(6):1839-47. PubMed ID: 12454841
[TBL] [Abstract][Full Text] [Related]
26. Albumin infusion in liver cirrhotic patients.
Rena NM; Wibawa ID
Acta Med Indones; 2010 Jul; 42(3):162-8. PubMed ID: 20724771
[TBL] [Abstract][Full Text] [Related]
27. Expert perspectives for the pharmacist on facilitating and improving the use of albumin in cirrhosis.
Kugelmas M; Loftus M; Owen EJ; Wadei H; Saab S
Am J Health Syst Pharm; 2023 Jun; 80(13):806-817. PubMed ID: 37013893
[TBL] [Abstract][Full Text] [Related]
28. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis.
Fernández J; Monteagudo J; Bargallo X; Jiménez W; Bosch J; Arroyo V; Navasa M
Hepatology; 2005 Sep; 42(3):627-34. PubMed ID: 16108036
[TBL] [Abstract][Full Text] [Related]
29. The use of albumin in all patients with decompensated cirrhosis is not justified.
Avidan B
Isr Med Assoc J; 2005 Feb; 7(2):118-20. PubMed ID: 15729967
[No Abstract] [Full Text] [Related]
30. Review article: albumin in the treatment of liver diseases--new features of a classical treatment.
Arroyo V
Aliment Pharmacol Ther; 2002 Dec; 16 Suppl 5():1-5. PubMed ID: 12423447
[TBL] [Abstract][Full Text] [Related]
31. Albumin in Advanced Liver Diseases: The Good and Bad of a Drug!
Jagdish RK; Maras JS; Sarin SK
Hepatology; 2021 Nov; 74(5):2848-2862. PubMed ID: 33772846
[TBL] [Abstract][Full Text] [Related]
32. Use of albumin in the management of patients with decompensated cirrhosis. An independent verdict.
Arroyo V; Colmenero J
Dig Liver Dis; 2003 Sep; 35(9):668-72. PubMed ID: 14563192
[TBL] [Abstract][Full Text] [Related]
33. Hepatorenal syndrome.
Guevara M; Ginès P
Dig Dis; 2005; 23(1):47-55. PubMed ID: 15920325
[TBL] [Abstract][Full Text] [Related]
34. Spectroscopic analysis of the impact of oxidative stress on the structure of human serum albumin (HSA) in terms of its binding properties.
Maciążek-Jurczyk M; Sułkowska A
Spectrochim Acta A Mol Biomol Spectrosc; 2015 Feb; 136 Pt B():265-82. PubMed ID: 25448930
[TBL] [Abstract][Full Text] [Related]
35. Renal failure in patients with cirrhosis: hepatorenal syndrome and renal support strategies.
Meltzer J; Brentjens TE
Curr Opin Anaesthesiol; 2010 Apr; 23(2):139-44. PubMed ID: 20124895
[TBL] [Abstract][Full Text] [Related]
36. Immune Dysfunction and Albumin-Related Immunity in Liver Cirrhosis.
Wilde B; Katsounas A
Mediators Inflamm; 2019; 2019():7537649. PubMed ID: 30930689
[TBL] [Abstract][Full Text] [Related]
37. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.
Moreau R; Lebrec D
Hepatology; 2006 Mar; 43(3):385-94. PubMed ID: 16496352
[TBL] [Abstract][Full Text] [Related]
38. Hypoalbuminemia.
Gatta A; Verardo A; Bolognesi M
Intern Emerg Med; 2012 Oct; 7 Suppl 3():S193-9. PubMed ID: 23073857
[TBL] [Abstract][Full Text] [Related]
39. [Current problems in the prevention and treatment of infections in patients with cirrhosis].
Bellot P; Jara Pérez López N; Martínez Moreno B; Such J
Gastroenterol Hepatol; 2010 Dec; 33(10):729-40. PubMed ID: 20444525
[TBL] [Abstract][Full Text] [Related]
40. Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival.
Oettl K; Birner-Gruenberger R; Spindelboeck W; Stueger HP; Dorn L; Stadlbauer V; Putz-Bankuti C; Krisper P; Graziadei I; Vogel W; Lackner C; Stauber RE
J Hepatol; 2013 Nov; 59(5):978-83. PubMed ID: 23811308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
